2-(Benzyloxy)-1-ethenyl-3-methoxybenzene

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-(Benzyloxy)-1-ethenyl-3-methoxybenzene
• 英文别名: 1-ethenyl-3-methoxy-2-phenylmethoxybenzene
• 化学式: C₁₆H₁₆O₂
• 分子量: 240.302
• InChiKey: FBJNSAKZQDQBLM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(Benzyloxy)-1-ethenyl-3-methoxybenzene 、 三氯乙酰氯 在 铜 、 锌 、 三氯氧磷 作用下， 以 乙醚 为溶剂， 反应 1.0h， 生成
  参考文献：
  名称：

  Asymmetric Synthesis of 3,4-Dihydrocoumarins by Rhodium-Catalyzed Reaction of 3-(2-Hydroxyphenyl)cyclobutanones

  摘要：

  3,4-Dihydrocoumarin derivatives were synthesized in a highly enantioselective manner from 3-(2-hydroxyphenyl)cyclobutanones through enantioselective carbon-carbon bond cleavage. A cascade reaction with electron-deficient alkenes introduced a carbon-carbon bond at the 5-position of the dihydrocoumarins.

  DOI：

  10.1021/ja075141g
• 作为产物：
  描述：

  2-苄氧基-3-甲氧基苯甲醛 、 alkaline earth salt of/the/ methylsulfuric acid 以 甲苯 为溶剂， 生成 2-(Benzyloxy)-1-ethenyl-3-methoxybenzene
  参考文献：
  名称：

  Asymmetric Synthesis of 3,4-Dihydrocoumarins by Rhodium-Catalyzed Reaction of 3-(2-Hydroxyphenyl)cyclobutanones

  摘要：

  3,4-Dihydrocoumarin derivatives were synthesized in a highly enantioselective manner from 3-(2-hydroxyphenyl)cyclobutanones through enantioselective carbon-carbon bond cleavage. A cascade reaction with electron-deficient alkenes introduced a carbon-carbon bond at the 5-position of the dihydrocoumarins.

  DOI：

  10.1021/ja075141g

文献信息

• Piperidine derivatives having ccr3 antagonism
  申请人：Matsumoto Yoshiyuki

  公开号：US20070032525A1

  公开（公告）日：2007-02-08

  The invention provides low molecular compounds having activity which inhibits binding of CCR3 ligands to CCR3 on target cells, i.e. CCR3 antagonists. The invention also provides compounds represented by formula (I) below, pharmaceutically acceptable acid adducts thereof, or pharmaceutically acceptable C 1 -C 6 alkyl adducts thereof, as well as pharmaceutical compositions comprising them as effective ingredients, which are useful for treatment or prevention of diseases associated with CCR3, such as asthma and allergic rhinitis.

  本发明提供了具有抑制CCR3配体结合到靶细胞CCR3的活性的低分子化合物，即CCR3拮抗剂。本发明还提供了由下式（I）表示的化合物，其药学上可接受的酸加合物或药学上可接受的C1-C6烷基加合物，以及包含它们作为有效成分的制药组合物，用于治疗或预防与CCR3相关的疾病，例如哮喘和过敏性鼻炎。
• 4,4-Disubstituted) piperidine derivatives having ccr3 antagonism
  申请人：Matsumoto Yoshiyuki

  公开号：US20070037851A1

  公开（公告）日：2007-02-15

  The invention provides low molecular compounds having activity which inhibits binding of CCR3 ligands to CCR3 on target cells, i.e. CCR3 antagonists. The invention also provides 4,4-(disubstituted)piperidine derivatives represented by formula (I) below, pharmaceutically acceptable acid adducts thereof, or pharmaceutically acceptable C 1 -C 6 alkyl adducts thereof, as well as pharmaceutical compositions comprising them as effective ingredients, which are useful for treatment or prevention of diseases associated with CCR3, such as asthma and allergic rhinitis.

  本发明提供了具有抑制CCR3配体与靶细胞上CCR3结合活性的低分子化合物，即CCR3拮抗剂。本发明还提供了由下式（I）所表示的4,4-(二取代)哌啶衍生物，其药学上可接受的酸加合物或药学上可接受的C1-C6烷基加合物，以及包含它们作为有效成分的药物组合物，用于治疗或预防与CCR3相关的疾病，如哮喘和过敏性鼻炎。
• [EN] AUTHENTICATION OF PRODUCTS USING MOLECULARLY IMPRINTED POLYMERS<br/>[FR] AUTHENTIFICATION DE PRODUITS AN MOYEN DE POLYMERES A EMPREINTE MOLECULAIRE
  申请人：UNIV JOHNS HOPKINS

  公开号：WO2005038734A2

  公开（公告）日：2005-04-28

  A method for identifying a product includes providing a solid body (10) fabricated from at least a molecularly imprinted polymer having molecular sized cavities (12) adapted to selectively receive and bind molecules (50) having a specific taggant molecular structure (51), the molecular sized cavities (12) disposed on a portion of an exterior surface (11) of the body (10), and applying to the surface of the body a composition containing indicator molecules (50) having a taggant moiety (51) at one end and a marking function group (53) tethered to the taggant moiety (51) by a molecular chain (52), the taggant moieties (51) engaging and binding to the molecular sized cavities (12) so as to mark the portion of the surface (11) of the body (10) with the indicator molecules (50) bound thereto, the marking functional groups (53) rendering the marked portion of the surface (11) perceptible with or without detection instrumentation.